SynthesisFrontiers in endocrinology2023
Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: A systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06121999 (13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease), which is not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatosis (MASH) in Adults: A Randomized Control Trial
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Pooled it
- Resistance training for metabolic dysfunction-associated steatotic liver disease:a systematic review and meta-analysis.Frontiers in physiology · 2025Pooled it
- Pooled it
- Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2024Pooled it
- A multifaceted lifestyle program for weight loss in overweight adults: evidence from a randomised clinical trial.European journal of nutrition · 2026Trial
- Odevixibat ameliorates high-fat diet-induced MASLD in mice by targeting the gut microbiota-metabolite axis and enhancing gut-liver crosstalk.Journal of physiology and biochemistry · 2026Article
- Prevalence and risk factors of metabolic dysfunction-associated fatty liver disease in the adult Georgian population: a nationwide multiregional clinic-based study.BMC gastroenterology · 2025Article
- Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Article
- Efficacy of structured exercise and oat supplementation for treating non-alcoholic fatty liver disease: protocol of a randomized controlled trial.Nutrition journal · 2025Article
- Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions.World journal of hepatology · 2025Article
- Efficacy of intermittent fasting on improving liver function in individuals with metabolic disorders: a systematic review and meta-analysis.Nutrition & metabolism · 2025Review
- Relationship of serum irisin levels, physical activity, and metabolic syndrome biomarkers in obese individuals with low-calorie intake and non-obese individuals with high-calorie intake.Journal of health, population, and nutrition · 2025Article
- Triglycerides/high-density lipoprotein-cholesterol ratio outperforms traditional lipid indicators in predicting metabolic dysfunction-associated steatotic liver disease among U.S. adults.Frontiers in endocrinology · 2025Article
- Association of healthy lifestyles with risk of all-cause and cause-specific mortality among individuals with metabolic dysfunction-associated steatotic liver disease: results from the DFTJ cohort.Annals of medicine · 2024Article
- Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024).Journal of clinical and translational hepatology · 2024Article
- Astaxanthin Alleviates Hepatic Lipid Metabolic Dysregulation Induced by Microcystin-LR.Toxins · 2024Article
- Review
- [Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Synergistic impact of Gui Zhi Shao Yao Zhi Mu Decoction and leflunomide on gut microbiota in rheumatoid arthritis: insights from 16S rDNA sequencing.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This systematic review and meta-analysis evaluates the overall effects of lifestyle interventions upon hepatic fat content and metabolism-related indicators among adults with metabolic associated fatty liver disease. Methods: It was registered under PROSPERO (CRD42021251527). We searched PubMed, EMBASE, MEDLINE, Cochrane, CINAHL, Scopus, CNKI, Wan-fang, VIP, and CBM from the inception of each database to May 2021 for RCT studies of lifestyle interventions on hepatic fat content and metabolism-related indicators. We used Review Manager 5.3 for meta-analysis and used text and detailed tabular summaries when heterogeneity existed. Results: Thirty-four RCT studies with 2652 participants were included. All participants were obesity, 8% of whom also had diabetes, and none was lean or normal weight. Through subgroup analysis, we found low carbohydrate diet, aerobic training and resistance training significantly improved the level of HFC, TG, HDL, HbA1c, and HOMA-IR. Moreover, low carbohydrate diet is more effective in improving HFC than low fat diet and resistance training is better than aerobic training in reduction in HFC and TG (SMD, -0.25, 95% CI, -0.45 to -0.06; SMD, 0.24, 95% CI, 0.03 to 0.44, respectively). Discussion: Overall, this is the first review that systematically synthesizes studies focused on the effects of various lifestyle on adults with MAFLD. The data generated in this systematic review were more applicable to obesity MAFLD rather than lean or normal weight MAFLD. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier (CRD42021251527).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.